ScreenerHero

AGEN Agenus Inc.

NAS · US · Healthcare · Biotechnology · agenusbio.com
7.570USD+1.07%Mkt Cap: 341.88M $P/E: 2.99

Agenus Inc., a clinical-stage biotechnology company, discovers and develops immunotherapies for cancer and infectious diseases in the United States and internationally. It offers Retrocyte Display, an antibody expression…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$128.08BUSDP/E 29.4
MRNA
Moderna, Inc.
$78.44BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$76.40BUSDP/E 18.4
ARGX
argenx SE
$57.03BUSDP/E 37.3
ARGX
argenx SE
$58.08BUSDP/E 35.4
UCB
UCB SA
$42.24BUSDP/E 18.0
RVMD
Revolution Medicines, Inc.
$43.05BUSD
ONC
BeOne Medicines AG
$41.41BUSDP/E 65.1
RPRX
Royalty Pharma plc
$32.80BUSDP/E 30.2
ALNY
Alnylam Pharmaceuticals, Inc.
$30.03BUSDP/E 37.8
ROIV
Roivant Sciences Ltd.
$25.10BUSD
BNTX
BioNTech SE
$23.93BUSD
INCY
Incyte Corporation
$22.99BUSDP/E 14.5
GMAB
Genmab A/S
$22.27BUSDP/E 30.7
GMAB
Genmab A/S
$22.54BUSDP/E 28.9
INSM
Insmed Incorporated
$22.22BUSD
ASND
Ascendis Pharma A/S
$15.03BUSDP/E 17.5
JAZZ
Jazz Pharmaceuticals plc
$15.01BUSDP/E 15.8
EXEL
Exelixis, Inc.
$14.48BUSDP/E 18.4
SMMT
Summit Therapeutics Inc.
$14.32BUSD

Key Statistics

Company
Market Cap341.88M USD
Enterprise Value352.40M USD
Revenue (TTM)132.69M USD
Gross Profit33.84M USD
Net Income (TTM)115.00K USD
Revenue/Share3.65 USD
Last Price7.570 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees81
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)2.99
P/E (Forward)-68.09
PEG1.44
EV/EBITDA8.68
EV/Revenue2.66
P/S2.55
P/B-1.60
EPS (TTM)2.53
EPS (Forward)-0.11
52W Range
2.71064% of range10.31
52W High10.31 USD
52W Low2.710 USD
Profitability
Gross Margin29.63%
Oper. Margin32.72%
EBITDA Margin30.60%
Profit Margin0.10%
ROE-0.04%
ROA0.05%
Growth
Revenue Growth34.40%
Earnings Growth—
Cash Flow & Leverage
Operating CF-77.19M USD
CapEx (TTM)6.00K USD
FCF Margin-56.36%
FCF Yield-21.88%
Net Debt21.97M USD
Net Debt/EBITDA0.54
Balance Sheet
Debt/Equity-0.21
Current Ratio0.34
Quick Ratio0.32
Book Value/Sh-4.67 USD
Cash/Share0.42 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split1:20
Split DateApr 12, 2024
Analyst Consensus
Rating1.0 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)26.33 USD
Upside (mean)+247.9%
Target Range14.00 USD – 40.00 USD
14.00+247.9% to mean40.00
# Analysts3
Ownership
Shares Out.45.16M
Float40.23M
Insiders6.27%
Institutions46.38%
Short Interest
Short Ratio6.8d
Short % Float15.24%
Short % Out.15.07%
Shares Short6.80M
Short (prev mo.)5.86M
Technical
SMA 507.796 (-2.9%)
SMA 2004.643 (+63.1%)
Beta1.32
S&P 52W Chg16.45%
Avg Vol (30d)1.14M
Avg Vol (10d)1.31M
Technical Indicators
RSI (14)45.8
MACD0.2567
MACD Signal0.4240
MACD Hist.-0.1673
BB Upper10.02 USD
BB Middle8.123 USD
BB Lower6.230 USD
BB Width46.61%
ATR (14)0.6898 USD
Vol Ratio (20d)0.96x